- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Simon Rule, MD: Subcutaneous Rituximab Versus an Intravenous Biosimilar
Simon Rule, MD, Plymouth University Medical School, discusses the role of biosimilar rituximab in the era of subcutaneous reference rituximab in oncology.
Transcript
I don’t know if you know that in the [United Kingdom, UK], biosimilar rituximab has taken the entire market. There’s no biosimilar subcutaneous, but the biosimilar intravenous basically has had a massive impact with respect to cost. The biosimilar that’s used in the UK was over 40% cheaper than the MabThera. From a healthcare system that buys a lot of drug, that’s a big, big impact. So from an intravenous point of view, we’re using the biosimilar. I don’t have a choice; that’s what we’re doing. But of course there's only 1 subcutaneous.
Certainly in the maintenance setting, the hidden costs of somebody being in a chair all afternoon versus the subcutaneous are massive. Even within the [National Health Service, NHS], that’s recognized. So subcutaneous within a maintenance setting is allowed. I think in maintenance, you need to give the subcutaneous. You could argue whether intravenous when you’re giving somebody intravenous chemotherapy is cost effective or not, and maybe it is because the patient is in the chair anyway. So that’s perhaps where you could argue for a biosimilar intravenous, but certainly maintenance, I don’t think there’s any role for an intravenous formulation over a subcutaneous one.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
